[{"id":"c67cb0cc-4062-4cc7-ac4c-e0358ba638bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT06986174","created_at":"2025-06-28T16:12:40.055Z","updated_at":"2025-06-28T16:12:40.055Z","phase":"Phase 2","brief_title":"A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia","source_id_and_acronym":"NCT06986174","lead_sponsor":"Shayna Sarosiek, MD","biomarkers":" MYD88 • CXCR4","pipe":" | ","alterations":" TP53 mutation","tags":["MYD88 • CXCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vonjo (pacritinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/01/2025","start_date":" 08/01/2025","primary_txt":" Primary completion: 10/01/2028","primary_completion_date":" 10/01/2028","study_txt":" Completion: 10/01/2032","study_completion_date":" 10/01/2032","last_update_posted":"2025-05-22"},{"id":"b75ecd93-1120-4cfc-9f9a-b68e1481f48d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05588141","created_at":"2022-10-20T14:11:44.038Z","updated_at":"2025-02-25T12:29:09.098Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations","source_id_and_acronym":"NCT05588141","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zotiraciclib (TG02)"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 05/16/2023","start_date":" 05/16/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/02/2029","study_completion_date":" 08/02/2029","last_update_posted":"2025-02-24"},{"id":"f4b4cbe0-4811-4846-aa3a-c12b65f5b2a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06052618","created_at":"2023-09-25T14:10:30.120Z","updated_at":"2025-02-25T12:29:50.276Z","phase":"Phase 2","brief_title":"Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)","source_id_and_acronym":"NCT06052618","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vonjo (pacritinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 02/27/2025","start_date":" 02/27/2025","primary_txt":" Primary completion: 01/01/2033","primary_completion_date":" 01/01/2033","study_txt":" Completion: 01/01/2034","study_completion_date":" 01/01/2034","last_update_posted":"2025-02-24"},{"id":"f98e10ef-ecf5-4a3d-b5b3-240b7e0bd849","acronym":"","url":"https://clinicaltrials.gov/study/NCT06439836","created_at":"2024-06-08T04:14:47.148Z","updated_at":"2025-02-25T14:11:06.436Z","phase":"Phase 1","brief_title":"Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy","source_id_and_acronym":"NCT06439836","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD68 • CRP","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • CD68 • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • emavusertib (CA-4948)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 02/21/2025","start_date":" 02/21/2025","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-18"},{"id":"002fe85e-b3d8-4f4c-9679-0e7ceacd8f48","acronym":"MCC-20963","url":"https://clinicaltrials.gov/study/NCT05177211","created_at":"2022-01-04T13:53:44.017Z","updated_at":"2025-02-25T14:16:34.238Z","phase":"Phase 2","brief_title":"Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)","source_id_and_acronym":"NCT05177211 - MCC-20963","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inrebic (fedratinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2025-02-13"},{"id":"99225106-dfaa-4574-8f8a-c62a8252d206","acronym":"","url":"https://clinicaltrials.gov/study/NCT04293562","created_at":"2021-01-18T20:50:03.431Z","updated_at":"2025-02-25T15:11:29.634Z","phase":"Phase 3","brief_title":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","source_id_and_acronym":"NCT04293562","lead_sponsor":"Children's Oncology Group","biomarkers":" FLT3","pipe":"","alterations":" ","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • etoposide IV • methotrexate • Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation) • mitoxantrone • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Erwinase (erwinia asparaginase) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate) • dexrazoxane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1186","initiation":"Initiation: 07/21/2020","start_date":" 07/21/2020","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-13"},{"id":"7246a629-768b-4557-b16c-b951baaa4ed1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03742258","created_at":"2021-01-18T18:19:49.340Z","updated_at":"2025-02-25T15:34:14.094Z","phase":"Phase 1","brief_title":"Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT03742258","lead_sponsor":"Northwestern University","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" MYC overexpression • MYC expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC overexpression • MYC expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Truxima (rituximab-abbs) • mivavotinib (CB-659) • Riabni (rituximab-arrx) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 03/13/2019","start_date":" 03/13/2019","primary_txt":" Primary completion: 03/12/2021","primary_completion_date":" 03/12/2021","study_txt":" Completion: 12/19/2028","study_completion_date":" 12/19/2028","last_update_posted":"2025-02-11"},{"id":"7ae66fef-a243-4d8f-b364-a73eb3507cdb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04633122","created_at":"2021-01-19T20:36:54.322Z","updated_at":"2025-02-25T15:34:48.949Z","phase":"Phase 2","brief_title":"A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib","source_id_and_acronym":"NCT04633122","lead_sponsor":"Zai Lab (Shanghai) Co., Ltd.","biomarkers":" KIT • PDGFRA","pipe":" | ","alterations":" KIT mutation • PDGFRA mutation","tags":["KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • sunitinib • Qinlock (ripretinib)"],"overall_status":"Completed","enrollment":" Enrollment 108","initiation":"Initiation: 11/25/2020","start_date":" 11/25/2020","primary_txt":" Primary completion: 07/20/2022","primary_completion_date":" 07/20/2022","study_txt":" Completion: 07/20/2022","study_completion_date":" 07/20/2022","last_update_posted":"2025-02-10"},{"id":"e3936c5c-e8c6-4488-bd75-cc3cc84c9df4","acronym":"NCI-2018-01789","url":"https://clinicaltrials.gov/study/NCT03661307","created_at":"2021-01-18T17:57:55.790Z","updated_at":"2025-02-25T15:25:53.725Z","phase":"Phase 1/2","brief_title":"Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT03661307 - NCI-2018-01789","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • FLT3","pipe":" | ","alterations":" TP53 mutation • FLT3-ITD mutation • FLT3 mutation • TP53 deletion","tags":["TP53 • FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3-ITD mutation • FLT3 mutation • TP53 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Vanflyta (quizartinib) • decitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 73","initiation":"Initiation: 10/31/2018","start_date":" 10/31/2018","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-10"},{"id":"569368a9-e762-49bc-b3b0-d10e7bc1381f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02390752","created_at":"2021-01-18T11:23:54.887Z","updated_at":"2025-02-25T16:58:46.439Z","phase":"Phase 1","brief_title":"Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...","source_id_and_acronym":"NCT02390752","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Turalio (pexidartinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 04/29/2015","start_date":" 04/29/2015","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-03"},{"id":"a154a323-d6ef-4152-926e-c4ab1ae75b5e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05756777","created_at":"2023-03-06T15:01:58.629Z","updated_at":"2025-02-25T15:36:05.770Z","phase":"Phase 1","brief_title":"A Study of Gilteritinib in Combination with Ivosidenib or Enasidenib in People with Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT05756777","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" FLT3 • IDH1 • IDH2","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation • FLT3 mutation","tags":["FLT3 • IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation • FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • Tibsovo (ivosidenib) • Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 06/26/2023","start_date":" 06/26/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-11-12"},{"id":"0586b97f-ca3e-4935-90c4-ce0d935a32d9","acronym":"NCI-2020-05261","url":"https://clinicaltrials.gov/study/NCT04493138","created_at":"2021-01-18T21:35:02.627Z","updated_at":"2024-07-02T16:34:59.952Z","phase":"Phase 1/2","brief_title":"Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations","source_id_and_acronym":"NCT04493138 - NCI-2020-05261","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • FLT3 • ASXL1","pipe":" | ","alterations":" TP53 mutation • FLT3-ITD mutation • ASXL1 mutation • CBL mutation","tags":["TP53 • FLT3 • ASXL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3-ITD mutation • ASXL1 mutation • CBL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Vanflyta (quizartinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 07/21/2020","start_date":" 07/21/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-30"},{"id":"3102105e-b831-48d9-b839-01e75ece3f9a","acronym":"COVALENT-103","url":"https://clinicaltrials.gov/study/NCT05918692","created_at":"2023-06-26T14:09:14.079Z","updated_at":"2024-07-02T16:35:00.712Z","phase":"Phase 1","brief_title":"A Phase 1, Study of BMF-500 in Adults With Acute Leukemia","source_id_and_acronym":"NCT05918692 - COVALENT-103","lead_sponsor":"Biomea Fusion Inc.","biomarkers":" FLT3 • NPM1","pipe":" | ","alterations":" FLT3 mutation • NPM1 mutation • FLT3 wild-type","tags":["FLT3 • NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • NPM1 mutation • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BMF-500"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 07/26/2023","start_date":" 07/26/2023","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2024-05-27"},{"id":"6705e7e6-5f76-403e-847f-2fbe43967ddb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05241106","created_at":"2022-02-15T15:52:44.070Z","updated_at":"2024-07-02T16:35:03.973Z","phase":"Phase 2","brief_title":"A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT05241106","lead_sponsor":"Tarapeutics Science Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HYML-122"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 09/29/2021","start_date":" 09/29/2021","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-05-14"},{"id":"f65efc53-8b60-4d72-9e77-531f3964de27","acronym":"","url":"https://clinicaltrials.gov/study/NCT05241093","created_at":"2022-02-15T15:52:43.789Z","updated_at":"2024-07-02T16:35:03.939Z","phase":"Phase 2","brief_title":"A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT05241093","lead_sponsor":"Tarapeutics Science Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • HYML-122"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 03/29/2022","start_date":" 03/29/2022","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-14"},{"id":"409da099-f4a0-4d19-8f1c-da9bf68bdd78","acronym":"DIAMOND-01","url":"https://clinicaltrials.gov/study/NCT03008187","created_at":"2021-05-17T08:53:01.393Z","updated_at":"2024-07-02T16:35:04.730Z","phase":"Phase 1/2","brief_title":"SEL24/MEN1703 in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT03008187 - DIAMOND-01","lead_sponsor":"Menarini Group","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dapolsertib (MEN1703)"],"overall_status":"Completed","enrollment":" Enrollment 73","initiation":"Initiation: 03/10/2017","start_date":" 03/10/2017","primary_txt":" Primary completion: 04/13/2023","primary_completion_date":" 04/13/2023","study_txt":" Completion: 04/13/2023","study_completion_date":" 04/13/2023","last_update_posted":"2024-05-09"},{"id":"46bd478e-b8d0-4e9c-a5fd-b1d6d75d3215","acronym":"","url":"https://clinicaltrials.gov/study/NCT02975700","created_at":"2021-01-18T14:37:44.830Z","updated_at":"2024-07-02T16:35:10.337Z","phase":"","brief_title":"A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma","source_id_and_acronym":"NCT02975700","lead_sponsor":"Daiichi Sankyo Co., Ltd.","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Turalio (pexidartinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 01/31/2017","start_date":" 01/31/2017","primary_txt":" Primary completion: 08/31/2018","primary_completion_date":" 08/31/2018","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-04-10"},{"id":"9b0dc769-7e69-4597-ba4b-209925af9306","acronym":"","url":"https://clinicaltrials.gov/study/NCT02891603","created_at":"2021-01-18T14:11:34.890Z","updated_at":"2024-07-02T16:35:12.946Z","phase":"Phase 1/2","brief_title":"A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression","source_id_and_acronym":"NCT02891603","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" IL6 • HLA-DRB1 • CD4 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["IL6 • HLA-DRB1 • CD4 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus • Vonjo (pacritinib)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 06/08/2017","start_date":" 06/08/2017","primary_txt":" Primary completion: 01/28/2022","primary_completion_date":" 01/28/2022","study_txt":" Completion: 04/18/2022","study_completion_date":" 04/18/2022","last_update_posted":"2024-03-25"},{"id":"e90cec53-ae6c-493e-9af7-3f156a05c47e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02400281","created_at":"2021-01-18T11:27:08.882Z","updated_at":"2024-07-02T16:35:13.589Z","phase":"Phase 1/2","brief_title":"Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients","source_id_and_acronym":"NCT02400281","lead_sponsor":"Arog Pharmaceuticals, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • etoposide IV • crenolanib (ARO-002) • idarubicin hydrochloride • mitoxantrone • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 07/15/2020","primary_completion_date":" 07/15/2020","study_txt":" Completion: 07/15/2020","study_completion_date":" 07/15/2020","last_update_posted":"2024-03-20"},{"id":"15953f0f-132c-44a4-9f39-8d36bdd31ec9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04278768","created_at":"2021-05-11T14:53:15.390Z","updated_at":"2024-07-02T16:35:15.352Z","phase":"Phase 1/2","brief_title":"Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With AML or MDS","source_id_and_acronym":"NCT04278768","lead_sponsor":"Curis, Inc.","biomarkers":" FLT3 • SF3B1 • U2AF1","pipe":" | ","alterations":" FLT3 mutation • SF3B1 mutation • U2AF1 mutation","tags":["FLT3 • SF3B1 • U2AF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • SF3B1 mutation • U2AF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • emavusertib (CA-4948)"],"overall_status":"Recruiting","enrollment":" Enrollment 366","initiation":"Initiation: 07/06/2020","start_date":" 07/06/2020","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-03-11"},{"id":"98f0842a-766f-4b08-a05c-7687c1fef2e9","acronym":"NCI-2018-01813","url":"https://clinicaltrials.gov/study/NCT01892371","created_at":"2021-01-18T08:29:57.401Z","updated_at":"2024-07-02T16:35:17.303Z","phase":"Phase 1/2","brief_title":"Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT01892371 - NCI-2018-01813","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • Vanflyta (quizartinib) • Starasid (cytarabine ocfosfate)"],"overall_status":"Completed","enrollment":" Enrollment 73","initiation":"Initiation: 11/12/2013","start_date":" 11/12/2013","primary_txt":" Primary completion: 02/07/2023","primary_completion_date":" 02/07/2023","study_txt":" Completion: 02/07/2023","study_completion_date":" 02/07/2023","last_update_posted":"2024-02-28"},{"id":"c372b4b4-4bc4-4fd8-9862-9add8d9bb685","acronym":"","url":"https://clinicaltrials.gov/study/NCT03922100","created_at":"2021-01-18T19:17:47.256Z","updated_at":"2024-07-02T16:35:18.417Z","phase":"Phase 1/2","brief_title":"Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML","source_id_and_acronym":"NCT03922100","lead_sponsor":"Nerviano Medical Sciences","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NMS-088"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 04/03/2019","start_date":" 04/03/2019","primary_txt":" Primary completion: 12/28/2025","primary_completion_date":" 12/28/2025","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2024-02-21"},{"id":"95b055b1-d7c0-4581-b32f-575eb60dd1f0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02283177","created_at":"2021-01-17T17:36:58.991Z","updated_at":"2024-07-02T16:35:21.166Z","phase":"Phase 2","brief_title":"A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations","source_id_and_acronym":"NCT02283177","lead_sponsor":"Arog Pharmaceuticals, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • crenolanib (ARO-002) • daunorubicin • idarubicin hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2024-02-02"},{"id":"3b2388de-8a3b-4895-8ff3-2c449923f3a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT01522469","created_at":"2021-01-18T06:24:20.054Z","updated_at":"2024-07-02T16:35:21.896Z","phase":"Phase 2","brief_title":"Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations","source_id_and_acronym":"NCT01522469","lead_sponsor":"Arog Pharmaceuticals, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e crenolanib (ARO-002)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 07/01/2012","start_date":" 07/01/2012","primary_txt":" Primary completion: 08/01/2014","primary_completion_date":" 08/01/2014","study_txt":" Completion: 11/01/2014","study_completion_date":" 11/01/2014","last_update_posted":"2024-01-30"}]